CUE BIOPHARMA INC's ticker is CUE and the CUSIP is 22978P106. A total of 75 filers reported holding CUE BIOPHARMA INC in Q3 2023. The put-call ratio across all filers is 1.21 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $143 | -47.6% | 62 | 0.0% | 0.00% | – |
| Q2 2023 | $273 | +35.1% | 62 | 0.0% | 0.00% | – |
| Q1 2023 | $202 | -96.6% | 62 | -97.0% | 0.00% | – |
| Q4 2022 | $6,000 | -94.4% | 2,062 | -95.7% | 0.00% | – |
| Q3 2022 | $107,000 | +11.5% | 48,262 | +24.5% | 0.00% | – |
| Q2 2022 | $96,000 | -96.0% | 38,762 | +1.5% | 0.00% | -100.0% |
| Q1 2022 | $2,407,000 | +699.7% | 38,182 | +43.4% | 0.01% | +400.0% |
| Q4 2021 | $301,000 | -33.8% | 26,620 | -14.7% | 0.00% | 0.0% |
| Q3 2021 | $455,000 | +92.0% | 31,220 | +52.9% | 0.00% | 0.0% |
| Q2 2021 | $237,000 | +18.5% | 20,420 | +24.4% | 0.00% | – |
| Q1 2021 | $200,000 | +9900.0% | 16,420 | +13583.3% | 0.00% | – |
| Q4 2020 | $2,000 | 0.0% | 120 | 0.0% | 0.00% | – |
| Q3 2020 | $2,000 | -33.3% | 120 | 0.0% | 0.00% | – |
| Q2 2020 | $3,000 | +50.0% | 120 | 0.0% | 0.00% | – |
| Q1 2020 | $2,000 | – | 120 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Prosight Management, LP | 1,510,282 | $7,370,000 | 4.76% |
| SANDERS MORRIS HARRIS LLC | 873,021 | $4,261,000 | 0.83% |
| P.A.W. CAPITAL CORP | 150,000 | $732,000 | 0.76% |
| Nantahala Capital Management | 2,244,359 | $10,952,000 | 0.48% |
| Bleichroeder LP | 552,000 | $2,694,000 | 0.48% |
| APOGEM CAPITAL LLC | 111,259 | $543,000 | 0.37% |
| Slate Path Capital LP | 1,483,619 | $7,240,000 | 0.37% |
| Robertson Stephens Wealth Management, LLC | 478,500 | $2,335,000 | 0.20% |
| CARLSON CAPITAL L P | 405,000 | $1,976,000 | 0.14% |
| Bridgefront Capital, LLC | 19,968 | $97,000 | 0.12% |